Incyte

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware.[2] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.[3]

Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

History

In June 2025, Incyte named Bill Meury president, CEO, and a member of the board of directors. He replaced Hervé Hoppenot, who retired after 11 years of service.[4]

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[5]

In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[6] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[7]

Incyte established a European headquarters in Morges, Switzerland, in 2021.[8]

Pharmaceuticals

Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).[9] [10] In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.[11]

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[12][13] It gained EU approval in February 2017.[14] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[15][16] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.[17][18]

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[19][20]

Acquisition history

Incyte has made a total of 3 acquisitions.

• Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million. [21]
• Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions. [22]
• Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.[23]

External links